NCT02444910 - Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

KDT501

600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.

Trial Locations (1)

University of Kentucky's Center for Clinical and Translational Science (CCTS), Lexington